Analysts have revised their price target for Terveystalo Oyj downward from €11.98 to €11.30. This change reflects slightly lower expectations for revenue growth and profit margins.
What's in the News
- Terveystalo reaffirmed its earnings guidance for 2025, expecting earnings per share to grow by an average of 10% per year. The company also indicated accelerated EPS growth as fewer items are expected to affect comparability (Key Developments).
Valuation Changes
- Fair Value Estimate has decreased from €11.98 to €11.30, indicating a modest reduction in the company's assessed worth.
- Discount Rate has risen slightly from 5.52% to 5.67%, which reflects a slightly higher perceived risk or cost of capital.
- Revenue Growth Forecast has been lowered from 2.88% to 1.97%, which suggests more conservative expectations for top-line expansion.
- Net Profit Margin projection has declined from 9.38% to 8.96%, showing expectations for slightly reduced profitability.
- Future P/E Ratio estimate has increased from 12.48x to 13.57x, which implies the stock may now be trading at a higher earnings multiple.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.